![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Publisher: Adis International
ISSN: 1173-5503
Source: PharmacoEconomics and Outcomes News, Vol.1, Iss.360, 2002-01, pp. : 10-10
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Infliximab improves QOL in active and fistulising Crohn's disease
Inpharma, Vol. 1, Iss. 1346, 2002-01 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Salmeterol/fluticasone propionate improves QOL vs budesonide in asthma
PharmacoEconomics and Outcomes News, Vol. 1, Iss. 393, 2002-01 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Pharmacokinetics of Budesonide (Entocort EC) Capsules for Crohns Disease
Clinical Pharmacokinetics, Vol. 43, Iss. 12, 2004-01 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Budesonide MRC offers new treatment option for Crohn's disease
Inpharma, Vol. 1, Iss. 1316, 2001-01 ,pp. :